Video

Understanding the Patient Selection Process for CTCL Treatment

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, explained whether the current advanced cutaneous T cell lymphoma (CTCL) treatment strategies available are applicable for all patients with advanced CTCL and how patients are selected for treatment.

Pharmacy Times interviewed Lauren C. Pinter-Brown, MD, FACP, professor in the Department of Dermatology and the Department of Medicine in the Division of Hematology and Oncology at UCI Health and Chao Family Comprehensive Cancer Center, on her recent presentation at the Society of Hematologic Oncology Annual Meeting 2021 conference on the treatment of advanced cutaneous T cell lymphoma (CTCL) in 2021.

During this discussion, Pinter-Brown explained whether the current advanced CTCL treatment strategies available are applicable for all patients with advanced CTCL and how patients are selected for treatment.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com
Image credit: Sebastian Kaulitzki | stock.adobe.com
Magnified bone marrow biopsy showing plasma cells with irregular nuclei and multiple myeloma tumor cells infiltrating normal hematopoietic tissue